Free Trial
→ Trump’s national nightmare is here (From Porter & Company) (Ad)tc pixel Free XLO Stock Alerts

Xilio Therapeutics (XLO) Institutional Ownership

Xilio Therapeutics logo
$0.74 -0.01 (-1.17%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 0.00 (-0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Institutional Ownership Changes (13F Filings) for Xilio Therapeutics (NASDAQ:XLO)

Current
Institutional Ownership
Percentage
54.29%
Number of
Institutional Buyers
(last 12 months)
10
Total
Institutional Inflows
(last 12 months)
$10.85M
Number of
Institutional Sellers
(last 12 months)
1
Total
Institutional Outflows
(last 12 months)
$10.20K
Get XLO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

XLO Institutional Buying and Selling by Quarter

Xilio Therapeutics Major Shareholders & Ownership History

Export to Excel
Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2025Bridgeway Capital Management LLC56,081$38K0.0%-21.1%0.108%
5/16/2025ADAR1 Capital Management LLC40,000$29K0.0%N/A0.077%
4/29/2025Avantax Planning Partners Inc.150,399$109K0.0%N/A0.290%
2/17/2025Trustees of Columbia University in the City of New York249,635$238K0.0%N/A0.568%
2/17/2025Balyasny Asset Management L.P.343,230$328K0.0%+26.0%0.781%
2/17/2025Aptus Capital Advisors LLC41,000$39K0.0%N/A0.093%
2/14/2025Gilead Sciences Inc.9,105,451$8.70M0.6%N/A20.713%
2/13/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114%
2/13/2025Renaissance Technologies LLC296,617$283K0.0%+11.4%0.675%
2/12/2025Geode Capital Management LLC358,422$342K0.0%+6.0%0.815%
2/12/2025Takeda Pharmaceutical Co. Ltd.1,475,121$1.42M5.3%N/A3.356%
2/6/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114%
11/16/2024Geode Capital Management LLC338,192$266K0.0%+85.0%0.769%
8/12/2024XTX Topco Ltd33,289$32K0.0%N/A0.076%
8/9/2024Renaissance Technologies LLC295,000$280K0.0%+18.3%0.799%
5/6/2024Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690%
4/22/2024PFG Investments LLC30,000$32K0.0%N/A0.087%
2/15/2024Octagon Capital Advisors LP1,785,000$982K0.2%-23.0%6.481%
11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047%
8/15/2022Laurion Capital Management LP142,900$417K0.0%N/A0.520%
7/27/2022Bailard Inc.36,632$107K0.0%N/A0.133%
5/16/2022Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567%
5/12/2022Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594%
2/15/2022Davidson Kempner Capital Management LP29,000$458K0.0%N/A0.109%
2/14/2022Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078%
2/14/2022Ghisallo Capital Management LLC30,000$480K0.0%N/A0.113%
2/14/2022Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791%
2/11/2022Granite Point Capital Management L.P.10,000$160K0.0%N/A0.038%
2/9/2022AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504%
2/8/2022Northern Trust Corp63,034$1.01M0.0%N/A0.236%
2/7/2022Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803%
2/7/2022RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406%
2/2/2022New York State Common Retirement Fund5,568$89K0.0%N/A0.021%
(Data available from 1/1/2016 forward)

XLO Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of XLO shares?

During the previous two years, 15 institutional investors and hedge funds held shares of Xilio Therapeutics. The most heavily invested institutionals were Gilead Sciences Inc. ($8.70M), Takeda Pharmaceutical Co. Ltd. ($1.42M), Atlas Venture Life Science Advisors LLC ($1.07M), Octagon Capital Advisors LP ($982K), Geode Capital Management LLC ($342K), Balyasny Asset Management L.P. ($328K), and Renaissance Technologies LLC ($283K).Learn more on Xilio Therapeutics' institutional investors.

What percentage of Xilio Therapeutics' stock is owned by institutional investors?

54.29% of Xilio Therapeutics' stock is owned by institutional investors. Learn more on XLO's institutional investor holdings.

Which institutional investors have been buying Xilio Therapeutics' stock?

Of the 12 institutional investors that purchased Xilio Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Gilead Sciences Inc. ($9.11M), Takeda Pharmaceutical Co. Ltd. ($1.48M), Trustees of Columbia University in the City of New York ($249.64K), Geode Capital Management LLC ($175.57K), Avantax Planning Partners Inc. ($150.40K), Raymond James Financial Inc. ($100.17K), and Renaissance Technologies LLC ($75.87K).

How much institutional buying is happening at Xilio Therapeutics?

Institutional investors have bought a total of 11,438,406 shares in the last 24 months. This purchase volume represents approximately $10.85M in transactions.

Which of Xilio Therapeutics' major shareholders have been selling company stock?

The following institutional investors have sold Xilio Therapeutics stock in the last 24 months: Bridgeway Capital Management LLC ($15K).

How much institutional selling is happening at Xilio Therapeutics?

Institutional investors have sold a total of 15,000 shares in the last 24 months. This volume of shares sold represents approximately $10.20K in transactions.


Related Companies

This page (NASDAQ:XLO) was last updated on 9/10/2025 by MarketBeat.com Staff
From Our Partners
GENIUS Act: The Plot to Seize Your Cash?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...
American Alternative | Sponsoredtc pixel
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...
Porter & Company | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
Wall Street Legend Names #1 ‘Hidden’ AI Stock
50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...
Chaikin Analytics | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel